Syndax Pharmaceuticals (NASDAQ: SNDX) and Vitae Pharmaceuticals (NASDAQ:VTAE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitabiliy, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Insider and Institutional Ownership

53.5% of Syndax Pharmaceuticals shares are held by institutional investors. Comparatively, 72.6% of Vitae Pharmaceuticals shares are held by institutional investors. 24.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 14.8% of Vitae Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Syndax Pharmaceuticals has a beta of 5.45, meaning that its share price is 445% more volatile than the S&P 500. Comparatively, Vitae Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.


This table compares Syndax Pharmaceuticals and Vitae Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Syndax Pharmaceuticals -3,861.72% -52.82% -41.67%
Vitae Pharmaceuticals -318,350.20% -53.70% -49.85%

Earnings & Valuation

This table compares Syndax Pharmaceuticals and Vitae Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Syndax Pharmaceuticals $1.22 million 179.41 -$48.05 million ($2.61) -4.59
Vitae Pharmaceuticals N/A N/A N/A ($1.93) -10.88

Vitae Pharmaceuticals has higher revenue, but lower earnings than Syndax Pharmaceuticals. Vitae Pharmaceuticals is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Syndax Pharmaceuticals and Vitae Pharmaceuticals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syndax Pharmaceuticals 0 0 9 0 3.00
Vitae Pharmaceuticals 0 6 0 0 2.00

Syndax Pharmaceuticals currently has a consensus target price of $26.17, indicating a potential upside of 118.24%. Vitae Pharmaceuticals has a consensus target price of $21.67, indicating a potential upside of 3.17%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Syndax Pharmaceuticals is more favorable than Vitae Pharmaceuticals.


Syndax Pharmaceuticals beats Vitae Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer’s disease, or Alzheimer’s. VTP-43742, the Company’s wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.